La Jolla Pharmaceutical (NASDAQ: LJPC) has scheduled a special shareholder meeting for Oct. 30 to vote on a plan of liquidation and dissolution. If approved, the biotech expects to satisfy remaining debts and distribute remaining cash to shareholders. With estimated cash of $4.4 million at the end of August, the company estimates the distribution to the company’s 66 million shareholders would fall between 2.8 cents and 4.5 cents a share.

Bruce V. Bigelow was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Follow @bvbigelow

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO
• Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs
• ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More